SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI is trending as investors discuss a recently closed, oversubscribed $200 million financing round and its potential impact on the company's growth trajectory ahead of earnings. Community members are weighing the significance of institutional backing against possible dilution, debating whether this move sets the stage for future acquisitions or indicates underlying financial challenges. The involvement of key partners like Microsoft and Google, as well as upcoming earnings on October 1st, are also central to the conversation.

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as the community rallies behind the self-proclaimed first ETF on Solana, anticipating substantial gains. Discussions center on accumulating the asset, with many highlighting the strong community and the potential for meme season to drive significant growth. Some users are pointing out the presence of known pumpers or scammers.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave ($CRWV) is trending due to a recently announced contract expansion with OpenAI, though the stock's price reaction has been muted, sparking debate about market skepticism and potential overvaluation. Community members are actively discussing potential manipulation and future price movements, with some expressing concerns about debt levels and insider selling. Despite the positive news, some traders are wary, citing technical indicators and broader market conditions.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts stock is trending due to reports that the videogame giant may go private in a deal potentially valued at $50 billion, with Silver Lake and Saudi Arabia's Public Investment Fund mentioned as part of the investor consortium. The community is actively discussing the potential deal's impact on game quality and the future direction of EA's popular franchises, with some expressing hope for improved games if the deal goes through.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to positive case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, which the community believes could lead to a buyout. Community members are discussing the stock's potential for a short squeeze given its low float, while others point to upcoming meetings and potential news catalysts. Some traders are noting the stock's high relative strength and volume, suggesting potential for further upward movement.

BTQ Technologies Corp

BTQ is trending as investors discuss the potential impact of a $300 million registration for dilution after its NASDAQ debut, with some expressing disappointment and others viewing it as a long-term buying opportunity. Community members are debating the company's valuation and revenue prospects in the quantum cybersecurity space, while awaiting news about Robinhood availability. Some investors remain bullish, citing a deal with Danal and the potential for BTQ to become a leader in quantum-safe technology.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending due to speculation and community buzz following the release of the second GTA VI trailer, despite the game's release being pushed to May 2026.  Enthusiasm remains high with investors focused on the long-term potential of GTA VI and its impact on the gaming industry, as well as potential revenue from recurring online engagement.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending amid discussions about government support and its role in the rare earth supply chain, with some seeing it as a beneficiary of efforts to counter China's dominance in the sector. Community members are weighing the stock's valuation and potential catalysts, including upcoming financial reports and long-term contracts. There's also debate around potential government deals as well as comparing it to other companies in the space.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals ($CRNX) is trending due to positive community sentiment surrounding the company's recent FDA approval of Palsonify, an oral treatment for acromegaly, which is viewed as a potential game changer in the endocrine space. The community is actively discussing price target upgrades and the potential for a short squeeze, with some drawing comparisons to other successful biotech trades. Some investors are also pointing to the company's strong financial position and pipeline as reasons for long-term optimism.

American Exceptionalism Acquisition Corp. A

American Exceptionalism Acquisition Corp. A ($AEXA) is trending as traders discuss a potential short squeeze, with some citing a tight float and accumulation patterns. The community is actively speculating about the company's targets, which include Energy, AI, DeFi, and Defense, while also referencing Chamath Palihapitiya's involvement with the SPAC. Some traders are comparing it to other SPACs and anticipating after-hours movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Encompass Health Opens First Connecticut Rehab Hospital in Danbury

EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.

HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal

Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study

Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.

Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks 

Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.

Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience

Biotech stocks gain momentum as M&A, AI-driven drug discovery, and new approvals fuel growth; Halozyme, Akero, Kiniska, ANI and Twist stand out.

Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day

Halozyme shines with strong growth and partnerships, while Synopsys struggles after earnings miss and lowered outlook.

5 Biotech Stocks Worth Adding to Your Portfolio Now 

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, AKRO, KSNA, ANIP and TWST in this volatile sector

Bull of the Day: Halozyme Therapeutics (HALO)

The Street bailed on HALO in the spring, right before a summer rally to new highs on strong growth

Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know 

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

HALO
Halozyme Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HALO News

HALO Halozyme Therapeutics Inc.